Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dongyun Tu"'
Autor:
Linyan Xu, Meng Zhang, Dongyun Tu, Ziyi Lu, Tianyi Lu, Dongshen Ma, Yi Zhou, Shuo Zhang, Yuhan Ma, Dongmei Yan, Xiangmin Wang, Wei Sang
The authors have requested that this preprint be removed from Research Square.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58c4a09c96911db1df135faca91e1fbb
https://doi.org/10.21203/rs.3.rs-1952984/v1
https://doi.org/10.21203/rs.3.rs-1952984/v1
Autor:
Wei Sang, Dongyun Tu, Meng Zhang, Yuanyuan Qin, Wenjing Yin, Xuguang Song, Cai Sun, Dongmei Yan, Xiangmin Wang, Lingyu Zeng, Zhenyu Li, Kailin Xu, Linyan Xu
Publikováno v:
Journal of Biochemical and Molecular Toxicology. 36
Burkitt lymphoma (BL) is an aggressive Epstein-Barr virus (EBV)-driven B-cell lymphoma characterized by the translocation and rearrangement of the c-Myc proto-oncogene. High-intensity multidrug chemotherapy regimens have a limited effect on the survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b29e0a80a33502be3a99cff419165ee
https://doi.org/10.1002/jbt.23117
https://doi.org/10.1002/jbt.23117
Autor:
Meng Zhang, Dongyun Tu, Cai Sun, Kailin Xu, Wei Sang, Xiangmin Wang, Yuanyuan Qin, Mengdi Liu, Jun Jiao, Linyan Xu, Xuguang Song, Feng Zhu, Dongmei Yan
Publikováno v:
Anti-cancer agents in medicinal chemistry. 22(8)
Background: Extranodal natural killer/T cell lymphoma (ENKTL) is an aggressive malignant non- Hodgkin's lymphoma (NHL) with a poor prognosis. Therefore, novel therapeutic biomarkers and agents must be identified for the same. KAT5 inhibitor, NU 9056,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3757583bc2e7a34a16c6b15ef4dccb1
https://pubmed.ncbi.nlm.nih.gov/34503423
https://pubmed.ncbi.nlm.nih.gov/34503423
Autor:
Ziyuan Shen, Shanlin Nie, Yuanyuan Qin, Dongyun Tu, Wei Sang, Xuguang Song, Zhenyu Li, Yuhan Ma, Yingliang Jin, Kailin Xu, Cai Sun, Linyan Xu, Zhenzhen Bian, Hang Zhou, Dongmei Yan
Publikováno v:
International journal of hematology. 114(2)
Vascular endothelial growth factor affects the invasiveness of solid tumors by regulating angiogenesis. However, it is not clear whether VEGF could be used to predict the prognosis of DLBCL in the era of rituximab-based immunotherapy. We conducted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::521b517e2348bb1bb42504a4fc21adff
https://pubmed.ncbi.nlm.nih.gov/33893987
https://pubmed.ncbi.nlm.nih.gov/33893987